RESEARCH TRIANGLE PARK, NC - Chimerix Inc., a biotechnology companydeveloping orally-available antiviral therapeutics, has named Kenneth I. Moch president and CEO.
Moch joined Chimerix as Chief Operating Officer in July 2009, bringing more than 25 years of experience in creating, managing and financing biomedical companies. Moch will also join the company’s board.
Moch has played an integral role in building several life science companies, having previously led Alteon Inc. and Biocyte Corporation as Chief Executive Officer. He also served as managing director, Healthcare Banking at ThinkEquity Partners.
Moch was a co-founderand vice president of The Liposome Company Inc. (acquired by Elan).
George Painter, Ph.D., Chimerix’s former president and CEO, has been named Chief Scientific Officer and chairman of the company’s board.
Painter will oversee Chimerix’s drug discovery and development efforts and seek opportunities to leverage the company’s proprietary platform capabilities and antiviral expertise in the advancement of important new medicines that address global health needs, the company says.
Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV),hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.
